Soliflow is a prescription medication for the symptomatic management of Overactive Bladder (OAB) in adults. OAB is a condition characterized by sudden, strong urges to urinate that can be challenging to manage.

This medication is a treatment option that may help control the involuntary bladder muscle activity. This action can support the bladder's capacity to hold urine, which may assist in reducing the need for frequent urination and urgency. Soliflow is utilized in clinical practice to manage the symptoms of OAB and related conditions, including urge urinary incontinence (accidental leakage) and Neurogenic Detrusor Overactivity (NDO).

Observed benefits may include better management of the condition's impact, which can help support a patient's overall quality of life.

---

Quick Fact

Quick Fact: Relief for Urinary Frequency

---

This section outlines the official population eligibility and non-eligibility for Soliflow as defined in government regulatory labeling.

---

Contraindications and Absolute Exclusions

Soliflow is contraindicated and must not be used in specific patient groups due to safety risks. These include individuals with urinary retention, gastric retention or other severe gastrointestinal conditions (like toxic megacolon), uncontrolled narrow-angle glaucoma, and Myasthenia Gravis. Use is also prohibited in patients with a known hypersensitivity to the drug or any of its components.

---

Restricted and Conditional Use

Eligibility is restricted in patients with certain types of organ impairment or when taking specific medications:

• Severe Renal Impairment (creatinine clearance < 30 mL/min) or Moderate Hepatic Impairment (Child-Pugh B): The maximum recommended dose is restricted to 5 mg once daily.
• Severe Hepatic Impairment (Child-Pugh C): Use is not recommended.
• Concomitant CYP3A4 Inhibitors: The maximum dose is limited to 5 mg once daily when taken with potent inhibitors like ketoconazole.

---

Age and Life Stages

• Pediatric Use: The tablet formulation is not established for use and not recommended in children and adolescents under 18 years of age.
• Pregnancy and Lactation: Use during pregnancy should occur only if clearly needed. The drug is not recommended during breastfeeding.

Soliflow Interactions with other medicines and products

Soliflow's interaction profile, documented by regulatory authorities, centers on the CYP3A4 metabolic pathway and potential additive pharmacodynamic effects.

---

Pharmacokinetic Interactions

Interacting Substance Category	Official Documentation Statement
Potent CYP3A4 Inhibitors (e.g., Ketoconazole, Ritonavir)	These medicines cause a significant increase in Soliflow’s systemic exposure (AUC), necessitating dose restriction or contraindication.
CYP3A4 Inducers (e.g., Rifampicin, Phenytoin)	Pharmacokinetic interactions are possible, potentially altering Soliflow’s plasma concentration.

Pharmacodynamic Interactions

• Other Anticholinergic Agents: Co-administration may result in more pronounced effects and undesirable outcomes due to an additive anticholinergic load.
• Cholinergic Receptor Agonists: The therapeutic action of Soliflow may be reduced by these co-administered agents.
• Medicinal Products Stimulating Gastro-Intestinal Motility (e.g., Metoclopramide): Soliflow can reduce the effect of these medicines by decreasing gastrointestinal tract motility.

Interaction Constraints and Timing Rules

• Contraindicated Combination: The co-administration of Potent CYP3A4 Inhibitors with Soliflow is formally restricted and is contraindicated in patients with severe renal impairment (Creatinine Clearance leq 30 mL/min) or moderate hepatic impairment (Child-Pugh B).
• Sequential Therapy: An interval of approximately one week must be allowed after discontinuing Soliflow before commencing other anticholinergic therapy.

Blockade of Cholinergic Signaling

Soliflow (Solifenacin succinate) functions exclusively by modulating the biological pathways that regulate smooth muscle control. The action is achieved by intervening in the specific nerve signaling responsible for initiating contraction. Soliflow acts as a competitive antagonist, engaging the muscarinic acetylcholine receptors ( M3 subtype) located on the smooth muscle cells of the bladder. By occupying the receptor site, the molecule prevents the binding of the neurotransmitter acetylcholine, thereby suppressing the primary chemical signal that causes the muscle to contract. This initial blockade interrupts the parasympathetic efferent pathway that is responsible for triggering detrusor contractility.

Cascade to Smooth Muscle Relaxation

The receptor blockade initiates a cascade that results in the functional relaxation of the detrusor muscle tissue. This molecular interruption prevents the cellular release of intracellular calcium ( Ca^2+), which is essential for the muscle fibers to shorten and generate force. The resulting reduction in smooth muscle tone and detrusor contractility leads directly to increased compliance of the bladder wall, which establishes the physiological capacity of the organ to store volume.

Soliflow (solifenacin succinate) is an antimuscarinic medication used for the treatment of overactive bladder symptoms, including urge urinary incontinence, urgency, and urinary frequency. This medication should be taken exactly as prescribed by a healthcare professional.

---

Administration and Dosing

Soliflow tablets are designed for oral use and should be swallowed whole with water. The tablets must not be crushed, broken, or chewed. This medication can be administered with or without food.

The typical starting dose for adults is 5 mg once daily. If the 5 mg dose is well tolerated but symptoms are not adequately controlled, the dose may be increased to 10 mg once daily.

---

Special Dosing Considerations	Maximum Recommended Dose
Severe Renal Impairment (CLcr < 30 mL/min/1.73 m^2)	5 mg once daily
Moderate Hepatic Impairment (Child-Pugh B)	5 mg once daily
Concomitant Use of Strong CYP3A4 Inhibitors (e.g., ketoconazole)	5 mg once daily

Soliflow is not recommended for use in patients with severe hepatic impairment (Child-Pugh C). Always consult a healthcare provider before making any changes to the prescribed dosage.

---

Missed Dose

If a dose is forgotten, it should be taken as soon as it is remembered, unless it is already time for the next scheduled dose. In such a case, the missed dose should be skipped. Patients should not take two doses to compensate for a missed dose.

Research evidence / Overview of studies for Soliflow

---

Evidence for Use in Overactive Bladder (OAB) in Adults

Research for Soliflow in adults with Overactive Bladder symptoms has primarily used short-term Randomized Controlled Trials (RCTs). These studies were conducted to compare the medicine against a placebo (an inactive treatment) over defined time intervals. Research explored how symptoms change over time by tracking a patient's experience with OAB, including the number of reported episodes of urgency and involuntary leakage (urge incontinence). The studies focused on adults aged 18 and older who were experiencing OAB symptoms.

In these trials, studies monitored changes in patient-reported outcomes describing perceived discomfort and physical discomfort. Research describes how the frequency of micturitions per day and episodes of urinary incontinence, as reported by study participants, evolved during the study period. Some trials reported differences in the patterns of change compared to those observed in the placebo group. Research examined changes measured during the study period related to daily functioning or activity level.

It is noted that OAB trials often encounter a high response rate in the control groups due to the observation that many participants report symptom changes even when receiving the placebo. This variability is noted in the evidence when contextualizing the findings. Additionally, the results apply only to the populations studied.

Studies Comparing Soliflow to Placebo

These core efficacy studies were relevant in trials assessing short-term or episodic symptom patterns, typically over about 12 weeks. The primary goal was to evaluate whether the study group patterns evolved differently compared to taking a placebo. The research monitored outcomes reflecting daily functioning, such as changes in urinary frequency and urgency, as reported by patients in diaries.

Evidence for Neurogenic Detrusor Overactivity (NDO) in Pediatric Patients

The research base for Soliflow's evaluation in children and adolescents with Neurogenic Detrusor Overactivity is derived from dedicated Phase 3 studies and subsequent open-label extension studies. NDO is a condition marked by functional limitations and involuntary bladder muscle activity due to a neurological condition. Research explored changes in the bladder's capacity to hold urine in this population.

Studies used objective urodynamic measures, which involve specialized testing to measure bladder function, specifically looking at the Maximum Cystometric Capacity (MCC). Research examined the functional imbalance and physical discomfort. Studies monitored how symptoms and bladder capacity evolved in the observed populations. The data show patterns related to a reduction in incontinence episodes per day.

Key Studies & References

1. Labeling for Solifenacin Succinate: Clinical Trials and Regulatory Review
2. NICE Guideline [NG123]: Lower urinary tract symptoms in women: management

Common questions about Soliflow (FAQ)

Q: What is Soliflow and how does it work?

A: Soliflow is a medication used to treat symptoms of overactive bladder (OAB), such as a strong, sudden need to urinate, frequent urination, and leakage of urine. Its active ingredient, solifenacin, belongs to a class of drugs called anticholinergics (or muscarinic receptor antagonists). Solifenacin works by helping to relax the smooth muscle of the bladder wall. This relaxation increases the bladder's capacity to hold urine and helps to reduce the feeling of urgency, which in turn decreases the frequency of urination.

---

Q: How long does it take for Soliflow to start working?

A: It may take some time before you notice the full benefit of Soliflow. While some people may feel an improvement in their symptoms within a few days to a week, the maximum therapeutic effect is often seen after about 4 to 12 weeks of consistent use. It is important to continue taking the medication as prescribed by your healthcare provider, even if you do not feel immediate results.

---

Q: What are the common side effects of Soliflow?

A: The most commonly reported side effects of Soliflow are related to its anticholinergic action. These can include:

• Dry mouth (xerostomia), which is the most frequent side effect.
• Constipation.
• Blurred vision.
• Dry eyes.

If these side effects are persistent or severe, you should talk to your healthcare provider. Your provider can offer management strategies or adjust your treatment.

---

Q: Can Soliflow interact with other medications?

A: Yes, Soliflow can interact with several types of medications, which may affect how Soliflow works or increase the risk of side effects. Key interactions include:

• Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): These drugs can increase the concentration of Soliflow in the body, potentially requiring a dose adjustment.
• Other anticholinergic medicines: Taking Soliflow with other anticholinergics (such as certain drugs for allergies, depression, or Parkinson's disease) can increase the risk of side effects like dry mouth and constipation.
• Drugs that stimulate gut motility (e.g., metoclopramide): Soliflow may decrease the effect of these medications.

Always provide your healthcare provider and pharmacist with a complete list of all the prescription, over-the-counter, and herbal products you are taking before starting Soliflow.

How to Store and Dispose of Soliflow (Solifenacin Succinate)

Soliflow must be stored at Controlled Room Temperature, which is typically 20 C to 25 C (68 F to 77 F). The medication must be kept in its original container and the container must remain tightly closed.

Storage Protection

Protect Soliflow from excess heat and moisture to maintain product stability. For safety, the medication must be stored out of the sight and reach of children.

Disposal

Soliflow is not on the list of medicines recommended for flushing down the toilet. Unused or expired medication should be discarded using an authorized drug take-back program. If a take-back option is unavailable, the tablets should be mixed with an unappealing substance, placed in a sealed container, and thrown into the household trash, following specific regulatory guidelines.